KIBRA, which activates the Hippo pathway by inducing the phosphorylation of LATS1/2 [133], interacts with Willin/FRMD6 in prostate cancer cells and normal prostate epithelial cell lines [134]. Here, FRMD6 is linked to prostate carcinoma.